ReviewMolecular neurobiology2025
Prefrontal Cortex Molecular Signatures of Chronically Socially Isolated Rats and Their Response to Fluoxetine Treatment.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite intensive scientific and clinical research, the pathophysiological mechanisms of major depressive disorder (MDD) are still not fully understood, impeding the discovery of new effective treatments. A significant clinical challenge is the delayed onset of antidepressant efficacy, which limits timely therapeutic intervention. Recent advances in proteomics and metabolomics offer new opportunities to explore these complexities at the molecular level. This review presents a comprehensive analysis of the biochemical alterations and affected molecular pathways associated with depressive-like behavior in adult male rats subjected to chronic social isolation stress (CSIS), a well-established rodent model of depression. Additionally, it examines the effects of fluoxetine, a selective serotonin reuptake inhibitor (SSRI) commonly used in MDD treatment, to uncover potential mechanisms underlying the drug's therapeutic action. By integrating mass spectrometry-based proteomic and metabolomic analyses of cytosolic, nonsynaptic mitochondrial, and synaptosomal-enriched fractions of the rat prefrontal cortex, an area crucially implicated in both clinical and animal models of depression, this review provides insights into state-specific molecular signatures. The findings discussed here contribute to a deeper understanding of the neurobiological basis of depression and offer novel insights into the biochemical mechanisms mediating antidepressant effects, with potential for the development of improved therapeutic strategies.
Indexed as
Identifiers
40323568What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.